APEIRON BIOLOGICS
APEIRON is a focused on the discovery and development of novel cancer immunotherapies. APEIRON’s lead clinical program APN401 is a first-in-class autologous cellular therapy to enhanc immune reactivity via an intracellular immune master checkpoint, Cbl-b. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. APEIRON’s development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
APEIRON BIOLOGICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2005-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.apeiron-biologics.com
Total Employee:
11+
Status:
Active
Contact:
+43 1 86565 77
Email Addresses:
[email protected]
Total Funding:
25 M EUR
Technology used in webpage:
Domain Not Resolving Nginx Facebook Sharer Product Schema Pinterest Microdata For Google Shopping Nginx 1.10 Jitsi Austrian Server Location
Similar Organizations
argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
Baseimmune
Baseimmune is a biotech startup founded to create the next generation of vaccines.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Enara Bio
Ervaxx is illuminating the immune interface to develop new cancer therapies.
New Amsterdam Pharma
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
NodThera
NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Tacalyx
Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA
Current Advisors List
Current Employees Featured
Founder
Investors List
Die Vienna Insurance Group
Die Vienna Insurance Group investment in Corporate Round - Apeiron Biologics
European Investment Bank
European Investment Bank investment in Debt Financing - Apeiron Biologics
Official Site Inspections
http://www.apeiron-biologics.com
Unable to get host informations!!!
More informations about "Apeiron Biologics"
APEIRON Biologics – Experts in Respiratory and Cancer …
APEIRON BIOLOGICS. APEIRON was founded to transform lives and take away the fear of suffering from cancer. As first Austrian biotech company, APEIRON Biologics developed a cancer immunotherapy product through to market …See details»
About us – APEIRON Biologics
More than 25 years of professional experience as Board member of companies such as Medigene AG, Shield Therapeutics plc, WILEX AG, Immunocore ltd. and Catherex Inc. as well as …See details»
Apeiron Biologics - Crunchbase Company Profile
APEIRON is a focused on the discovery and development of novel cancer immunotherapies. APEIRON’s lead clinical program APN401 is a first-in-class autologous cellular therapy to enhanc immune reactivity via an intracellular …See details»
APEIRON Biologics AG - Life Sciences Directory
APEIRON Biologics AG at a glance: APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments …See details»
APEIRON Biologics AG - LinkedIn
APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer ...See details»
Apeiron Biologics - Overview, News & Similar companies - ZoomInfo
Apr 26, 2022 Apeiron Biologics contact info: Phone number: (210) 858-7070 Website: www.apeiron-biologics.com What does Apeiron Biologics do? Apeiron Biologics is a privately …See details»
APEIRON Biologics Company Profile 2024: Valuation, Investors ...
APEIRON Biologics General Information Description. Developer of antibodies intended to combat cancer and respiratory diseases. The company develops autologous cell therapies to …See details»
APEIRON shareholders approve new group structure …
Apr 26, 2022 APEIRON Biologics is a privately held biotech company based in Vienna, Austria. APEIRON received EU marketing approval for APN311 (dinutuximab beta, Qarziba®) in 2017 for the treatment of ...See details»
Apeiron Biologics - Funding, Financials, Valuation & Investors
Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies. Search Crunchbase. Start Free Trial . Chrome Extension. ... How …See details»
Apeiron Biologics AG - Life-Sciences-Europe.com
APEIRON Biologics has an approved product on the market, Qarziba®, for the treatment of pediatric neuroblastoma patients, which is outlicensed to and distributed worldwide by EUSA …See details»
APEIRON shareholders approve new group structure geared …
VIENNA, Austria, April 26, 2022 (GLOBE NEWSWIRE) -- APEIRON Biologics AG announces that the annual general meeting held yesterday has approved the new structure of the group …See details»
PR invIOs - APEIRON Biologics
Dec 16, 2021 About APEIRON Biologics AG APEIRON Biologics is a privately held biotech company based in Vienna, Austria. APEIRON received EU marketing approval for APN311 …See details»
Life Sciences Directory: APEIRON Biologics AG
Organization type RDM biotech/pharma Region Vienna Cluster LISAvienna Focus human health Profile. APEIRON Biologics AG at a glance: APEIRON Biologics is a privately held European …See details»
Apeiron Biologics - Company Profile - Tracxn
Nov 17, 2024 Apeiron Biologics ranks 563rd among 2408 active competitors. 870 of its competitors are funded while 548 have exited. Overall, Apeiron Biologics and its competitors …See details»
Ligand to Acquire APEIRON Biologics AG for $100 Million
JUPITER, Fla.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics …See details»
Ligand Pharma to acquire Apeiron Biologics
Jul 10, 2024 Apeiron Biologics received EMA marketing autorisation for APN311 (dinutuximab beta in 2017 for the treatment of high-risk neuroblastoma in infants aged twelve months and …See details»
APEIRON Biologics AG strengthens shareholder structure and …
APEIRON Biologics AG strengthens shareholder structure and Supervisory Board with international anchor investor. British investor consortium Franklin Road Ltd. increases its stake …See details»
Phase 2 Clinical Trial of APN01 for Treatment of COVID-19 Inititated
Apr 2, 2020 APEIRON Biologics AG today announced that it has received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II clinical trial of APN01 to treat COVID …See details»
invIOs goes live with unique cell therapy platform ... - APEIRON …
Like almost all websites, we also use cookies. Most of them we need to ensure the functionality of our website, others are used to analyze your user behavior ("non-technically necessary …See details»
Press releases – APEIRON Biologics
APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million Vienna, Austria, 8 July 2024: APEIRON Biologics AG (“APEIRON”), a leading Austrian biotech …See details»